108235-14-9

Basic information

• Product Name: 1,3,4,5,6-penta-O-benzyl-2-O-methanesulfonyl myo-inositol
• Synonyms: 1,3,4,5,6-penta-O-benzyl-2-O-methanesulfonyl myo-inositol
• CAS NO: 108235-14-9
• Molecular Weight: 708.873
• Mol File: 108235-14-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1,3,4,5,6-penta-O-benzyl-2-O-methanesulfonyl myo-inositol(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,4,5,6-penta-O-benzyl-2-O-methanesulfonyl myo-inositol(108235-14-9)
• EPA Substance Registry System: 1,3,4,5,6-penta-O-benzyl-2-O-methanesulfonyl myo-inositol(108235-14-9)

Safety Data

• Hazardous Substances Data: 108235-14-9(Hazardous Substances Data)

Upstream product

• 6195-45-5 meso-1,3,4,5,6-penta-O-benzyl-myo-inositol 
• 124-63-0 methanesulfonyl chloride 
• 28140-40-1 1,4,5,6-tetra-O-benzyl-myo-inositol 
• 100-44-7 benzyl chloride 
• 57029-85-3 1,4,5,6-tetra-O-benzyl-2,3-O-cyclohexylidene-sn-myo-inositol 
• 57029-87-5 (±)-1,2-cyclohexylidene myo-inositol 
• 87-89-8 D-myo-inositol 
• 26276-99-3 rac-1,4,5,6-tetra-O-benzyl-myo-inositol 
• 114218-29-0 (+/-)-1-O-allyl-2,3,4,5,6-pentakis-O-benzyl myo-inositol 
• 6691-27-6 (+/-)-cis-1,2-O-cyclohexylidene-3,4,5,6-tetrakis-O-benzyl myo-inositol 
• 10583-42-3 (+/-)-1-O-allyl-3,4,5,6-tetrakis-O-benzyl myo-inositol 
• 6763-47-9 rac-1,2-O-cyclohexylidene-myo-inositol 
• 6195-45-5 DL-2,3,4,5,6-penta-O-benzyl-myo-inositol 

Downstream Products

• 134275-55-1 Hexadecanoic acid 1-hexadecanoyloxymethyl-3-((1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentakis-benzyloxy-cyclohexyloxysulfonyl)-propyl ester 
• 134275-54-0 3,4-Dihydroxy-butane-1-sulfonic acid (1S,2S,3R,4S,5S,6S)-2,3,4,5,6-pentakis-benzyloxy-cyclohexyl ester 
• 134275-54-0 3,4-Dihydroxy-butane-1-sulfonic acid (1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentakis-benzyloxy-cyclohexyl ester 
• 134275-56-2 myo-inositol 1-(-3,4-di-palmitoyloxybutyl)-sulfonate 
• 134275-56-2 myo-inositol 1-(-3,4-di-palmitoyloxybutyl)-sulfonate 
• 108235-15-0 2,3,4,5,6-Penta-O-benzyl-1-O-hexanoyl-scyllo-inosit 
• 108341-48-6 Hexa-O-benzyl-scyllo-inosit 
• 134275-55-1 DL-2,3,4,5,6-penta-O-benzoyl-myo-inositol 1-<(S)-3,4-bis(palmitoyloxy)butanesulfonate> 
• 134275-54-0 (S)-3,4-Dihydroxy-butane-1-sulfonic acid (1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentakis-benzyloxy-cyclohexyl ester 
• 134275-56-2 DL-myo-inositol 1-<(S)-3,4-bis(palmitoyloxy)butanesulfonate> 
• 22132-86-1 meso-2,3,4,5,6-O-pentabenzyl-scyllo-inositol 
• 134275-53-9 2-(2,2-Dimethyl-[1,3]dioxolan-4-yl)-ethanesulfonic acid (1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentakis-benzyloxy-cyclohexyl ester 
• 134275-53-9 2-(2,2-Dimethyl-[1,3]dioxolan-4-yl)-ethanesulfonic acid (1S,2S,3R,4S,5S,6S)-2,3,4,5,6-pentakis-benzyloxy-cyclohexyl ester 
• 134275-53-9 DL-2,3,4,5,6-penta-O-benzyl-myo-inositol 1-<(S)-3,4-(isopropylidenedioxy)butanesulfonate> 

Relevant articles and documents

ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER

The present disclosure relates to pharmaceutical compositions including a compound derived from a parent compound having a hydroxyl or amino moiety, wherein the hydroxyl in the parent compound is presented as an ester in the compound or the amino in the parent compound is presented as an amide in the compound, and their use to prevent or treat neurological disease.

AN APPROACH TOWARD THE SYNTHESIS OF RACEMIC MYO-INOSITOL 1-( 3,4-DI-PALMITOYLOXYBUTYL)-SULFONATE

Substitution of the triflate function in 1,2-isopropylidene-sn-glycerol 3-trifluoromethanesulfonate by the α-lithio-anion of 2,3,4,5,6-penta-O-benzyl-myo-inositol 1-methanesulfonate afforded, after acid hydrolysis of the acetonide function, followed by pa